MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

14.65 -0.65 (-4.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Highlight VOWST™ Data at IDWeek
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Named to TIME100 Most Influential Companies List
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story